You are here

Open

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.


If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

  1. PA-19-076 : Enabling Technologies to Accelerate Development of Oral Biodevices (R43/R44 Clinical Trial Not Allowed)

    Release Date: 11-26-2018Open Date: 03-05-2019 Due Dates: Multiple Close Date: 01-05-2022

    Purpose This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  2. PA-19-075 : Enabling Technologies to Accelerate Development of Oral Biodevices (R41/R42 Clinical Trial Not Allowed)

    Release Date: 11-26-2018Open Date: 03-05-2019 Due Dates: Multiple Close Date: 01-05-2022

    Purpose This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  3. PAR-20-109: Non-Viral Technologies for in vivo Delivery of Genome Editors (R41/R42 Clinical Trial Not Allowed)

    Release Date: 02-06-2020Open Date: 03-05-2020 Due Dates: Multiple Close Date: 01-06-2022

    Research Objectives Maximizing the therapeutic impact of somatic genome editing requires the development of safe and effective technologies to deliver genome editing machinery into all disease-relevant somatic cells and tissues. Therefore, the objective of this FOA is to support the development and evaluation of innovative approaches to deliver genome editing machinery into somatic cells, with th ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  4. PAR-20-098: Non-Viral Technologies for in vivo Delivery of Genome Editors (R43/R44 Clinical Trial Not Allowed)

    Release Date: 02-06-2020Open Date: 03-05-2020 Due Dates: Multiple Close Date: 01-06-2022

    Research Objectives Maximizing the therapeutic impact of somatic genome editing requires the development of safe and effective technologies to deliver genome editing machinery into all disease-relevant somatic cells and tissues. Therefore, the objective of this FOA is to support the development and evaluation of innovative approaches to deliver genome editing machinery into somatic cells, with th ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  5. RFA-GM-22-001: IDeA Regional Entrepreneurship Development (I-RED) Program (STTR) (UT2 Clinical Trial Not Allowed)

    Release Date: 10-07-2021Open Date: 12-05-2021Due Date: 01-05-2022Close Date: 01-06-2022

    Background The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, also known as America’s seed fund, support US-owned and operated small businesses to engage in federal research and development that has a strong potential for commercialization. NIH’s SBIR and STTR programs invest over 1.2 billion dollars into health and life science companies tha ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  6. RFA-TR-21-010: Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 Clinical Trial Required)

    Release Date: 01-13-2021Open Date: 03-13-2021 Due Dates: Multiple Close Date: 01-13-2022

    A. Overview While there are thousands of rare diseases, the number of underlying etiologies is much smaller. Moreover, many disease etiologies underly multiple traditional diseases. This is most readily seen for rare monogenic diseases, where the most common etiologies include premature termination codons, protein misfolding, and abnormal RNA splicing. Other examples of rare disease shared molecu ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  7. RFA-DA-22-018: Advancing Validated Drug Targets for Substance Use Disorders (R41/R42- Clinical Trial Not Allowed)

    Release Date: 07-29-2021Open Date: 01-18-2022Due Date: 02-18-2022Close Date: 02-19-2022

    Background Substance use disorders (SUDs) affect people from all walks of life and all age groups. These illnesses are common, recurrent, and often serious, but they are treatable, and many people recover. SUDs occur when the recurrent use of drugs cause clinically significant impairment, including health problems, disability, and failure to meet major responsibilities at work, school, or home. T ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  8. RFA-DA-22-023: Advancing Validated Drug Targets for Substance Use Disorders (R43/R44- Clinical Trial Not Allowed)

    Release Date: 07-29-2021Open Date: 01-18-2022Due Date: 02-18-2022Close Date: 02-19-2022

    Background Substance use disorders (SUDs) affect people from all walks of life and all age groups. These illnesses are common, recurrent, and often serious, but they are treatable, and many people recover. SUDs occur when the recurrent use of drugs causes clinically significant impairment, including health problems, disability, and failure to meet major responsibilities at work, school, or home. ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  9. PAR-20-130: SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1 Clinical Trial Required)

    Release Date: 07-10-2020Open Date: 08-08-2020 Due Dates: Multiple Close Date: 04-06-2022

    Purpose The NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs have provided the small business community with critical seed funding to support the development of a wide variety of technologies that benefit society. The main objective in SBIR/STTR Phase I is to establish the technical merit and feasibility of the proposed research and development ( ...

    SBIRPhase IIDepartment of Health and Human ServicesNational Institutes of Health
  10. PAR-20-128: SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance (SB1, Clinical Trial Not Allowed)

    Release Date: 07-10-2020Open Date: 08-08-2020 Due Dates: Multiple Close Date: 04-06-2022

    Section I. Funding Opportunity Description Purpose The NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs have provided the small business community with critical seed funding to support the development of a wide variety of technologies that benefit society. The main objective in SBIR/STTR Phase I is to establish the technical merit and feasibility ...

    SBIRPhase IIDepartment of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government